Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“Since only 30%–50% of colorectal cancers have KRAS mutations [4,18,21], there has been speculation that the detection of KRAS mutation may portend a worse prognosis.”
BackgroundHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095 · cited 1×
“addition, miRNA expression is often lost in cancer because they tend to be located in genomic regions that are frequently lost during cancer development [67].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 4×
“The reduced expression of let-7 in cancer tissues corresponds to significantly higher levels of KRAS mRNA [70].”
BackgroundInfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690 · cited 1×
“Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Cited by
Items 201–252 of 252
Inhibitors of CRD-BP-KRAS RNA interaction
Wang, C. (2016) · doi:10.24124/2016/58894 · Cited by 2
Tokgün, O., Karagenç, N., Tokgün, P. E., Kubilay, I. N. C. I., Akça, H., Doğu, G. G., & Demiray, A. (2022) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1015438
The Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
Keskin, S. E., Guzdolu, E., Sertdemir, N., Demir, G., Akkoyunlu, D. S., Çabuk, D., Çine, N., & Savlı, H. (2022) · Kocaeli Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30934/kusbed.1052876 · Cited by 1
Wang, S., & Zhu, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03145-1
“As a proto-oncogene, KRAS participates in many important intracellular signaling pathways and significantly impacts cell division, differentiation, and proliferation.”
ResultInfluentialTHE ROLE OF CYTOKINES AND CHEMOKINES IN COLORECTAL CANCER DEVELOPMENT
Kit, O. I., Vladimirova, L. Y., Sagakyants, A. B., Викторовна, Т. А., Zlatnik, E. Y., Dzhenkova, E. A., & Novikova, I. A. (2023) · Современные проблемы науки и образования · doi:10.17513/spno.32805
Recent advances in molecular pathological findings in sinonasal carcinomas
Yamamoto, H. (2023) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.135.123
Bramantya, P. A. R., Wihandani, D. M., Dewi, N. N. A., & Ruma, I. M. W. (2024) · E-Jurnal Medika Udayana · doi:10.24843/mu.2024.v13.i03.p13
Sang, S. L. M. C., Páez, V. C. L., & Jiménez, Y. M. (2024) · Ciencia y Salud · doi:10.22206/cisa.2024.v8i2.pp65-74
Karabulut, B., & Çakar, B. (2024) · Case Reports in Oncology · doi:10.1159/000535202
“For example, KRAS , a major oncogenic driver in multiple cancers, is mutated in 30 – 40% of CRC tumors and demonstrates prognostic variability depending on mutation status [19, 20].”
BackgroundPredicting tumour evolution and drug resistance from heterogenous longitudinal cancer dataPreprint
Santacatterina, G., Bergamin, R., Zucchetto, A., Laureana, R., Principe, M. I. D., Gattei, V., Egidi, L., & Caravagna, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.30.630757
“Given the leading role of RAS among colorectal cancer driver genes 46–48 , this might suggest that RAS mutations confer strong positive selection (percentage increase of about 200”
Ottaviano, K. E., Subbaram, S., Wu, L., Stahl, K., Mastrangelo, A. J., Lee, H., & DiPersio, C. M. (2025) · Cancers · doi:10.3390/cancers17030371
“KRAS gene mutations are correlated with tumor aggressiveness and poor prognosis, and they are acquired in 40–45% of CRC patients, mainly at the transition from low-to high-grade dysplasia [11,12].”
Wu, J., Jiang, S., Shen, Q., & Gong, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15008 · Cited by 1
“KRAS mutations are among the most extensively studied and are distinctively characterized oncogenic alterations, occurring in 17‑25% of all cancers, with a prevalence of ~9% in GC and 30‑40% in CRC (63,64).”
Ghosh, B., Ava, F. K., Ferdoushi, A., Al‐Juboori, A. A. A., Karim, M. F., & Rahman, M. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5245388
Al-Mistarehi, A.-H. W., Khalilullah, T., Ghaith, A. K., Shafi, M., Khalifeh, J. M., Xia, Y., Zaitoun, K. J., Alnasser, A. A., Rajasekaran, J., Albert, A. N., et al. (2025) · Cancers · doi:10.3390/cancers17111739
“The prognostic value of KRAS mutations remains debated; while some studies, like Arrington et al., suggest an unfavorable prognosis associated with KRAS mutations in late-stage CRCs, other studies, including our own, have not found a significant association [31].”
Ablation Studies of KRAS in Colon Cancer: Predictive Power and Diagnostic Accuracy
Duvvuri, V., Kuracha, M. R., Shaw, Y., Ren, Z., Konduri, S., & Chintalapati, R. (2025) · Communications in computer and information science · doi:10.1007/978-981-96-6403-0_22
ZHUANG, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396860
The roles of ADAM9 in colorectal cancer cells
Chandrasekera, P. (2021) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/snhf-c504
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891408
Fattahi, F., Kiani, J., Alemrajabi, M., Soroush, A., Naseri, M., Najafi, M., & Madjd, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14759504
Parakrama, R., Fogel, E. J., Chandy, C., Augustine, T. A., Coffey, M., Tesfa, L., Goel, S., & Maitra, R. (2020) · Figshare · doi:10.6084/m9.figshare.12510866
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891402
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891417
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891405
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891420
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891414
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Figshare · doi:10.6084/m9.figshare.12891411
ZHUANG, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396857
Afonso, M. E. V. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Arana Garrido, R., & Arana Garrido, R. (2023) · UA Campus Repository (The University of Arizona)
Thornton, L. (2023) · Nottingham ePrints (University of Nottingham) · Cited by 1
Maimekov, U., Nosrati, M., Mahmoud, A., Mustafi, M., Craige, M. W., Coffman, F. D., Parrott, J. S., Lutz, C. S., & Mitrofanova, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-35903-w
Diagnostic, prognostic, and predictive cancer biomarkers in cancer theraputic approaches
Mridha, P., Biswas, A., Das, R., & Baishya, R. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2026.01.013
Sayed, M. E., Harati, M. E., Shealy, M. W., & Youssef, S. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01439-5 · Cited by 1
Étude épidémiologique et moléculaire des cancers colorectaux dans une région de l’ouest Algérien
Dahmani, B. (2024) · Dépôt Institutionnel de lUniversité de Tlemcen
Shahr, R. S., Mahmoudi, M. S., Amirnia, N., Karimpour, F., Noori, A., Khanmirzaei, A., Hasannia, T., Karimikhoshnoudian, B., Nasiri, P., & Javanmard, A. (2026) · Discover Oncology · doi:10.1007/s12672-026-04773-z
Rôle des cadhérines classiques dans l'invasion tumorale pancréatique
Dobric, A. (2020) · theses.fr (ABES) · doi:10.70675/dd65f036z5519z4d37z864fzfe059f41c75a
Oreiby, M. A.-E., Said, W. M., Gad, O. A. E.-F., & Hussein, F. Z. (2026) · Tanta Medical Journal · doi:10.4103/tmj.tmj_38_24
Marletta, S., Fiorini, D., Caliò, A., Marcolini, L., Stefanizzi, L., Giacometti, C., Pedron, S., Vicentini, C., & Martignoni, G. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04536-9
“Interestingly, KRAS-mutated neoplasms in other organs, such as the pancreas [45], lung[46], and colon[47], are associated with a poor prognosis, in contrast to the indolent biological behavior observed in PRNRP.”
Medeiros, A. B. D., Kozak, V. N., Picanço-Albuquerque, C. G., Neto, F. G. K. V., dos Santos, G. O., Aguiar, S., da Rocha, J. C. C., Carraro, D. M., & Torrezan, G. T. (2026) · Human Mutation · doi:10.1155/humu/6589780
Wiharjanto, D. E. N., Adnyana, I. B. B. S., & Hayuningrat, P. K. (2026) · International Surgery Journal · doi:10.18203/2349-2902.isj20261562
“11 However, our data showed that metastasis occurred almost equally in both groups (43.8% in the mutant group vs. 50.0% in the wild - type group).”
InfluentialRashid, S., Kakuturu, A., Muzammil, Z., & Parkash, H. (2026) · Cureus · doi:10.7759/cureus.110083
Hasbullah, H. H. (2022) · Universiti Sains Malaysia Institutional Repository (Universiti Sains Malaysia)
Liu, Y., Siegfried, G., Pernot, S., He, Z., Martín-Bórnez, M., Tejpar, S., Castanet, F., Desolneux, G., Évrard, S., Steinmetzer, T., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03875-w
Zhou, G., Dong, X., & Liu, L. (2026) · Cureus · doi:10.7759/cureus.112738
Mustawan, M. R. A., Adnyana, I. B. B. S., Hayuningrat, P. K., & Prayasti, N. K. S. (2026) · International Surgery Journal · doi:10.18203/2349-2902.isj20262444
“4,16,17 These mutations result in the constitutive activation of the RAS-RAF-MEK-ERK signaling pathway, driving oncogenic processes such as cellular proliferation and evasion of apoptosis.”
Evaristo, G., Farag, M. S., Wanjari, P., Mitchell, A., Guter, J., Shergill, A. P., Liao, C., Polite, B., Wang, P., Tjota, M. Y., et al. (2026) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2026.09.001
Londoño, M., Castro, C., Ana, C., Ruiz, S., Pedraz, J., & Osorio, M. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70272
“Additionally, synthetic and semi-synthetic matrices, including alginate-and polyethylene glycol-based hydrogels, have been developed to improve physicochemical tunability and reproducibility while preserving the ability to support spheroid-like formation across multiple cancer models [ 16, 19 ].”
Uncovering a novel mechanism of MET receptor endocytic trafficking
Viera, M. C. (2026) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke) · doi:10.71892/11143/2061
Metadata
- Authors
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J.
- Affiliations
- City Of Hope National Medical Center (US)
- University of Southern California (US)
- Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 11597, USA
- Corresponding author
- Arrington, Amanda K.
- Kim, Joseph
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-25
- Volume
- 13
- Issue
- 10
- Pages
- 12153-12168
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3497263
- OpenAlex
- W1991898744
- Cited by
- 244
- References
- 86
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 16 · 2021: 28 · 2020: 29 · 2019: 22 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 15 · 2014: 20 · 2013: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer, prognostic factors, predictive biomarkers, ras gene family, treatment resistance, tumor aggressiveness, survival
- MeSH terms
- Humans, Polymorphism, Genetic, Prognosis, Colorectal Neoplasms, ras Proteins, MicroRNAs, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


